Shares of US biotoech firm X4 Pharmaceuticals (Nasdaq: XFOR) closed down 2.56% at $6.10 yesterday, despite the company gaining a coveted regulatory designation for its lead drug candidate mavorixafor.
X4 pharma announced that the US Food and Drug Administration has granted Rare Pediatric Disease (RPD) designation for mavorixafor, for the treatment of WHIM (Warts, Hypogammaglobulinemia, Infections and Myelokathexis) syndrome, a rare, inherited, primary immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene.
Mavorixafor is currently being investigated in a global pivotal Phase III clinical trial, 4WHIM, for the treatment of WHIM syndrome in patients who are 12 years of age and older.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze